Associate Professor of Internal Medicine, Director of Lymphoid Malignancies Program UT Southwestern Medical Center Dallas, Texas
Learning Objectives:
Assess current treatment options for CLL/SLL beyond the current chemoimmunotherapy (CIT) standard
Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with major emerging agents, including Anti CD-20 mABs, BCL-2 inhibitors, and BTK inhibitors
Incorporate patient preferences and AE management strategies into patient centered treatment decisions.
Explain the genetic characteristics of CLL/SLL, including 17p deletions, and how gene mutation status affects patient outcomes in response to targeted therapies